Human papillomavirus vaccine recombinant octavalent (Merck)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHuman papillomavirus vaccine recombinant octavalent (Merck)

Drug Alias NameOctavalent HPV VLP vaccine - MerckOctavalent human papillomavirus (types 6, 11, 16, 18, 31, 45, 52, and 58) L1 virus-like particle vaccine - MerckV-502

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsVulvar NeoplasmsVaginal NeoplasmsUterine Cervical Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMerck & Co Inc Csl Behring Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMerck Sharp & Dohme LLC

Active IndicationsN/A

Inactive IndicationsVulvar NeoplasmsVaginal NeoplasmsUterine Cervical Neoplasms +[5]

Other Information

ATC CodeN/A